I would give that scenario (which is as bullish for MNTA as an outright FDA rejection of Teva’s ANDA) a 15% probability of occurring by the end of 2011.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”